Advertisement
Canada markets close in 6 hours 3 minutes
  • S&P/TSX

    23,885.23
    -116.32 (-0.48%)
     
  • S&P 500

    5,700.27
    -9.27 (-0.16%)
     
  • DOW

    41,908.50
    -288.02 (-0.68%)
     
  • CAD/USD

    0.7384
    -0.0024 (-0.32%)
     
  • CRUDE OIL

    71.87
    +1.77 (+2.52%)
     
  • Bitcoin CAD

    81,526.49
    -1,478.15 (-1.78%)
     
  • XRP CAD

    0.70
    -0.09 (-11.23%)
     
  • GOLD FUTURES

    2,668.60
    -1.10 (-0.04%)
     
  • RUSSELL 2000

    2,183.01
    -12.00 (-0.55%)
     
  • 10-Yr Bond

    3.8150
    +0.0300 (+0.79%)
     
  • NASDAQ

    17,951.45
    +26.33 (+0.15%)
     
  • VOLATILITY

    19.70
    +0.80 (+4.20%)
     
  • FTSE

    8,271.81
    -19.05 (-0.23%)
     
  • NIKKEI 225

    38,552.06
    +743.30 (+1.97%)
     
  • CAD/EUR

    0.6688
    -0.0013 (-0.19%)
     

What Kind Of Shareholder Owns Most HLS Therapeutics Inc. (TSE:HLS) Stock?

Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card!

A look at the shareholders of HLS Therapeutics Inc. (TSE:HLS) can tell us which group is most powerful. Institutions often own shares in more established companies, while it's not unusual to see insiders own a fair bit of smaller companies. Warren Buffett said that he likes 'a business with enduring competitive advantages that is run by able and owner-oriented people'. So it's nice to see some insider ownership, because it may suggest that management is owner-oriented.

HLS Therapeutics is a smaller company with a market capitalization of CA$453m, so it may still be flying under the radar of many institutional investors. Our analysis of the ownership of the company, below, shows that institutional investors have bought into the company. Let's take a closer look to see what the different types of shareholder can tell us about HLS.

Check out our latest analysis for HLS Therapeutics

TSX:HLS Ownership Summary, May 1st 2019
TSX:HLS Ownership Summary, May 1st 2019

What Does The Institutional Ownership Tell Us About HLS Therapeutics?

Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.

As you can see, institutional investors own 19% of HLS Therapeutics. This suggests some credibility amongst professional investors. But we can't rely on that fact alone, since institutions make bad investments sometimes, just like everyone does. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see HLS Therapeutics's historic earnings and revenue, below, but keep in mind there's always more to the story.

TSX:HLS Income Statement, May 1st 2019
TSX:HLS Income Statement, May 1st 2019

It looks like hedge funds own 32% of HLS Therapeutics shares. That worth noting, since hedge funds are often quite active investors, who may try to influence management. Many want to see value creation (and a higher share price) in the short term or medium term. While there is some analyst coverage, the company is probably not widely covered. So it could gain more attention, down the track.

Insider Ownership Of HLS Therapeutics

The definition of company insiders can be subjective, and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. The company management answer to the board; and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board, themselves.

I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions.

Our information suggests that insiders maintain a significant holding in HLS Therapeutics Inc.. Insiders have a CA$49m stake in this CA$453m business. It is great to see insiders so invested in the business. It might be worth checking if those insiders have been buying recently.

General Public Ownership

The general public, with a 11% stake in the company, will not easily be ignored. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders.

Private Equity Ownership

Private equity firms hold a 27% stake in HLS. This suggests they can be influential in key policy decisions. Some investors might be encouraged by this, since private equity are sometimes able to encourage strategies that help the market see the value in the company. Alternatively, those holders might be exiting the investment after taking it public.

Next Steps:

I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too.

I like to dive deeper into how a company has performed in the past. You can access this interactive graph of past earnings, revenue and cash flow, for free .

But ultimately it is the future, not the past, that will determine how well the owners of this business will do. Therefore we think it advisable to take a look at this free report showing whether analysts are predicting a brighter future.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.